![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF780B |
Gene summary for ZNF780B |
![]() |
Gene information | Species | Human | Gene symbol | ZNF780B | Gene ID | 163131 |
Gene name | zinc finger protein 780B | |
Gene Alias | ZNF779 | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R0P7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
163131 | ZNF780B | HTA12-23-1 | Human | Pancreas | PDAC | 2.61e-02 | 5.32e-01 | 0.3405 |
163131 | ZNF780B | HTA12-26-1 | Human | Pancreas | PDAC | 3.73e-05 | 4.42e-01 | 0.3728 |
163131 | ZNF780B | HTA12-29-1 | Human | Pancreas | PDAC | 9.33e-19 | 5.19e-01 | 0.3722 |
163131 | ZNF780B | male-WTA | Human | Thyroid | PTC | 1.04e-03 | 5.84e-02 | 0.1037 |
163131 | ZNF780B | PTC01 | Human | Thyroid | PTC | 2.42e-02 | 2.89e-02 | 0.1899 |
163131 | ZNF780B | PTC04 | Human | Thyroid | PTC | 3.04e-11 | 1.49e-01 | 0.1927 |
163131 | ZNF780B | PTC05 | Human | Thyroid | PTC | 4.54e-08 | 3.18e-01 | 0.2065 |
163131 | ZNF780B | PTC06 | Human | Thyroid | PTC | 3.44e-11 | 2.09e-01 | 0.2057 |
163131 | ZNF780B | PTC07 | Human | Thyroid | PTC | 1.27e-12 | 1.69e-01 | 0.2044 |
163131 | ZNF780B | ATC13 | Human | Thyroid | ATC | 9.53e-49 | 7.64e-01 | 0.34 |
163131 | ZNF780B | ATC2 | Human | Thyroid | ATC | 3.29e-02 | 3.68e-01 | 0.34 |
163131 | ZNF780B | ATC5 | Human | Thyroid | ATC | 5.63e-43 | 8.15e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF780B | SNV | Missense_Mutation | novel | c.1245N>T | p.Lys415Asn | p.K415N | Q9Y6R6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF780B | SNV | Missense_Mutation | novel | c.770N>A | p.Ser257Tyr | p.S257Y | Q9Y6R6 | protein_coding | deleterious(0.03) | probably_damaging(0.976) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF780B | SNV | Missense_Mutation | c.1424N>A | p.Cys475Tyr | p.C475Y | Q9Y6R6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR | |
ZNF780B | SNV | Missense_Mutation | c.2323N>T | p.His775Tyr | p.H775Y | Q9Y6R6 | protein_coding | deleterious(0.01) | benign(0.14) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
ZNF780B | SNV | Missense_Mutation | rs773076131 | c.2123N>G | p.Tyr708Cys | p.Y708C | Q9Y6R6 | protein_coding | tolerated(0.2) | possibly_damaging(0.665) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
ZNF780B | SNV | Missense_Mutation | c.1688N>A | p.Gly563Glu | p.G563E | Q9Y6R6 | protein_coding | tolerated(0.09) | probably_damaging(0.982) | TCGA-E2-A14Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD | |
ZNF780B | insertion | Frame_Shift_Ins | novel | c.378_379insGCTGAGTA | p.Arg127AlafsTer3 | p.R127Afs*3 | Q9Y6R6 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ZNF780B | SNV | Missense_Mutation | rs750610455 | c.1373N>G | p.Tyr458Cys | p.Y458C | Q9Y6R6 | protein_coding | tolerated(0.1) | benign(0.006) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF780B | SNV | Missense_Mutation | novel | c.1153G>T | p.Gly385Cys | p.G385C | Q9Y6R6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF780B | SNV | Missense_Mutation | rs752891232 | c.736N>G | p.Lys246Glu | p.K246E | Q9Y6R6 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |